Celares GmbH
Home  |  Contact  |  Imprint
celares GmbH celares GmbH celares GmbH celares GmbH celares GmbH
 
 
 

News release

News release

Merck Millipore and celares GmbH
announce collaboration

New: Discrete 4-arm-PEG Maleimide

New: Discrete 4-arm-PEG Maleimide

The multimerisation with discrete 4-arm PEG facilitates defined linker lenght according to binding requirments

Hydrophilic linkers for ADCs

Hydrophilic linkers for ADCs

celares PEG based linker increase solubility of hydrophobic cytotoxic drugs

PEGylation

PEGylation is an effective method for optimizing biopharmaceutical drugs. Coupling with PEG molecules results in considerably greater protease stability, a significant decrease in immunogenicity and a perceptible delaying of renal excretion.

Discrete PEG

HPLC analysis of discrete and polydisperse PEG:
(A) dPEG® is non-dispersed resulting in one single signal
(B) Polydispers PEG reagents are inhomogeneous HPLC analysis of discrete and polydisperse PEG: (A) dPEG® is non-dispersed resulting in one single signal (B) Polydispers PEG reagents are inhomogeneous

The term "dPEG®" is Quanta BioDesign's trademarked acronym for "discrete poly-(ethylene glycol)" or "discrete PEG". Like traditional PEGs, these products contain a hydrophilic, water-soluble backbone consisting of repeating ethylene oxide units; however unlike traditional PEGs each of our products represents a single compound with a unique, specific, single molecular weight (MW). dPEG® products are synthesized from pure building blocks (e.g. triethylene glycol or tetraethylene glycol) in a series of step-wise reactions to provide specific MWs, architectures, functional groups, and organic moieties suited for a wide variety of applications. These products have now been used for the modification of therapeutic macromolecules, as linkers in antibody-drug conjugates (ADCs), for bioconjugation of biologics, for surface modification, and in diagnostics, to name a few.

Quanta BioDesign is a partner of celares GmbH.

The manufacturing of discrete PEG is covered by patents that are proprietary to QuantaBioDesign.

Branched-PEG

 The unique properties of celares’ branched CelaSYS-reagents are summarized in the following table. The unique properties of celares’ branched CelaSYS-reagents are summarized in the following table.

The technological basis of the CelaSYS product line is a core branching unit to which PEG chains can be attached according to the technical needs. Whereas in traditional PEGylation chain-like structures are attached to the drug molecule, celares GmbH uses branched PEG structures with increased solubility. Furthermore, CelaSYS PEG is the ideal basis for increasing the payload of bio molecules with high potential small molecule drugs, e.g. for the manufacturing of antibody drug conjugates (ADCs). In such cases, CelaSYS is structured hetero-bifunctional facilitating the coupling of a defined number of small molecule drugs to a biological targeting molecule.

Furthermore, by using dPEG® for the attachment to the branching unit, large non-dispersed mono-activated PEG-reagents can be produced.

Branched CelaSYS PEG is covered by patents WO2004108634 and WO2007025763.